AR201 / Nestle - LARVOL DELTA

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy (clinicaltrials.gov) - P2 | N=15 | Terminated | Sponsor: Aimmune Therapeutics, Inc. | Completed ➔ Terminated; The study was prematurely terminated by the Sponsor based on difficulties in meeting enrollment goals, especially during the COVID-19 pandemic, and not for reasons relating to any concerns regarding quality, safety, or efficacy.

Trial termination • Allergy • Food Hypersensitivity • Immunology

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy (clinicaltrials.gov) - P2; N=15; Completed; Sponsor: Aimmune Therapeutics, Inc.; Active, not recruiting ➔ Completed; N=84 ➔ 15

Enrollment change • Trial completion • Allergy • Food Hypersensitivity • Immunology

Aimmune Therapeutics announces first quarter 2020 financial results and provides recent operational highlights (Businesswire) - "Upcoming milestones- 4Q 2020: Expected EMA action date for PALFORZIA in the European Union; 1H 2021: Expected data from POSEIDON Phase 3 clinical trial; Expect data from Phase 2 clinical trial of AR201 in patients with egg allergy; Mid-2021: Expected Swissmedic action date for PALFORZIA in Switzerland."

European regulatory • P2 data • P3 data • Allergy • Food Hypersensitivity • Immunology

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy (clinicaltrials.gov) - P2; N=84; Active, not recruiting; Sponsor: Aimmune Therapeutics, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

Aimmune proves its worth with latest FDA approval; other candidates left to advance (SeekingAlpha) - "The egg allergy indication is being evaluated in a phase 2 study using the product AR201 for 82 patients with egg allergy. This mid-stage study was initiated in August of 2019 and recruited children, adolescents, and young adults with egg allergy."

Trial status

Aimmune Therapeutics announces third quarter 2019 financial results and provides operational highlights (Businesswire) - "H2 2020 Expected completion of enrollment of AR201 phase 2 trial."

Enrollment status